Umbilical cord blood (UCB) banking has become a new obstetrical trend. It offers expectant parents a biological insurance policy that can be used in the event of a child or family member's life-threatening illness and puts patients in a position of control over their own treatment options. However, its graduation to conventional therapy in the clinical realm relies on breakthrough research that will prove its efficacy for a range of ailments. Expanding the multipotent cells found within the mononuclear fraction of UCB so that adequate dosing can be achieved, effectively expanding desired cells ex vivo, establishing its safety and limitations in HLA-mismatched recipients, defining its mechanisms of action, and proving its utility in a wide variety of both rare and common illnesses and diseases are a few of the challenges left to tackle. Nevertheless, the field is moving fast and new UCB-based therapies are on the horizon.
WHY UMBILICAL CORD BLOOD?
which is crucial for histocompatibility and avoidance of graft-versus-host disease (GvHD) in this type of allograft, 4) the National Donor Marrow Program has a New sources of stem/progenitor cells that can replace lost or diseased cells of the body are being sought due strong European bias, making it difficult to find sufficient matches for people of other descents (17) , 5) BM to tight government restrictions, availability, and ethical considerations regarding the use of embryonic and fetal recipients have a high incidence of viral infection (90%) (5), and 6) patients with malignancies are often unable tissues. Of these, bone marrow (BM) is the current gold standard source of hematopoietic progenitor cells (HPC) to use BM autografts because of the risk of reinfection with tumorgenic cells. used to reconstitute blood lineages after myeloablative therapy in a number of malignant and nonmalignant Umbilical cord blood (UCB), a once discarded material, has shown both in the lab and clinically to circum-blood diseases (21) . Bone marrow transplantation was first performed in the 1960s and is currently the treat-vent a number of these BM transplantation complexities. UCB cell transplantation made its clinical debut in 1988 ment of choice for more than 15,000 patients worldwide each year (1) . Allogenic and autogenic marrow can re-when it was used to successfully treat a 5-year-old child afflicted with Fanconi anemia (27) . Subsequently, more constitute erythrocytes, platelets, granulocytes, T-and B-lymphocytes, macrophages, osteocytes, Langerhans' than 6,000 UCB transplants have been performed worldwide, many of them with unrelated donors (4, 41, 69, 76) . cells, Kupffer's cells, and microglia (1) . However, only 30% of eligible patients have a matched donor enabling Like BM, UCB use has thus far been limited to hematopoietic malignancies, marrow failure, and immunodefi-them to receive its life-saving capability (2) . The most notable BM transplantation disadvantages include: 1) ciency disorders (Table 1) , but current research suggests it may be a much more powerful clinical weapon. UCB's The average length of time from commencement of the donor search to procurement of BM cells and treatment relative cellular immaturity compared to adult sources suggests a potentially unrivaled degree of plasticity. Its is 135 days (38) , 2) the cost of locating a donor and harvesting the cells is considerable, ranging from $25,000 use as an alternative to BM transplantation continues to grow as research better defines its composition, mecha-to $50,000 (38) , 3) there is a low availability of human leukocyte antigen (HLA)-matched donors with BM, nisms of action, and broad therapeutic capacity. (22) than adult cell sources (27) . Furthermore, of the mRNA • Epstein-Barr virus (32) that is expressed in UCB, the anti-inflammatory cyto-
• Lysosomal and peroxisomal storage diseases (46) kines interferon-γ (INF-γ), interleukin (IL)-4 and IL-10
• Diamond-Blackfan anemia (75) are more abundant than for the proinflammatory cyto-
• Various acute and chronic leukemias (55) kine IL-2 (27). This lack of mature immune function is
• Non-Hodgkin's lymphoma (55) attributed to UCB's low incidence of GvHD and viral
• Hodgkin's lymphoma (45) transmission. Such cellular constitution could allow for
• Sickle-cell anemia (55) less stringent donor-recipient matching requirements,
• Cooley's anemia (33) hence leading to shorter waiting period for treatment.
• Hurler syndrome (23) Rocha (57) found that GvHD incidence was signifi-
• Leukocyte adhesion deficiency (63) cantly lower in children receiving UCB transplants com-
• Evans syndrome (52) pared to BM recipients when the source was from an
• Osteopetrosis (61) HLA-identical sibling. Rocha (56) also demonstrated a
• Spinal cord injury (37) lower GvHD incidence in unrelated HLA-mismatched UCB recipients compared to HLA-identical BM recipients. illustrates the currently known advantages to the use of The enthusiasm over UCB began when it was found UCB over adult stem/progenitor cell sources such as to contain a large population of hematopoietic stem/pro-BM and adult peripheral blood (APB).
genitor cells compared to adult sources. These easily procured, low immunogenic sources of multipotential WHAT IS UCB COMPOSED OF?
cells are thought to have the capability to become any The cellular component of UCB is primarily comtype of cell in the body under specific conditions. Not prised of lymphocytes and monocytes (51) . It has a comonly does the MNF contain roughly 1% CD34 + cells, a parable B-lymphocyte population and a lower absolute marker designated for its role in early hematopoiesis, number of T-lymphocytes (CD3 + ) but a higher CD4 + / but these cells appeared to be more immature than those CD8 + ratio compared to APB (29, 51) . UCB also has found in BM. In general, the level of maturity of a cell higher numbers of NK cells while lower numbers of is identified by the cell's presence of or lack of a combi-CD56 + cytotoxic T-lymphocytes (18). UCB's relative nation of cell surface antigens. For instance, the CD34 + immaturity compared to adult cell sources is further population in UCB can be defined as more primitive classified as showing a higher proportion of immature than those found in BM because a higher proportion (4×) of them are negative for CD38, a marker for prelymphoid cells (12, 17) . Another subset of CD34 + cells in fetal brain.
• Immediately available and easily shipped.
A nonhematopoietic stem cell, the mesenchymal stem
• There is a high immune tolerance of UCB cells because they cell (MSC), has also been found in UCB; however, in are unable to generate cytotoxic T-Lymphocytes, which remuch lower numbers than in BM (28, 82) . The MSC can spond to allogenic antigens. UCB cells are also unable to
give rise to such diverse phenotypes as osteoblasts, synthesize the proinflammatory cytokines interferon-γ (IFNγ) chondroblasts, adipocytes, and hematopoietic and neural and tumor necrosis factor-α (TNFα) (58). • UCB has an abundant source (ϳ1% of the mononuclear frac-cells (astrocytes and neurons) (35, 39) . Identification of tion) of both hematopoietic and nonhematopoietic stem/prothis cell population is challenging because it currently genitor cells, which is comparable BM (64, 65) . lacks a definitive phenotype as well as agreement on UCB's more primitive, nonnucleated stem/progenitor cell component, which requires more time to reconsti-defined the MSC as positive for CD73, CD90, CD105, and CD166 and negative for CD31, CD34, CD45, tute platelets and infection-fighting granulocytes. Global expansion of the MNC from a typical UCB CD80, and HLA-DR. Universal agreement on a phenotype of these cells needs to first be reached before their unit is not the greatest technical feat. Though the correct cell/kg body weight dosage is important, it is the number true abundance in UCB can be known. Regardless, it is of a general consensus that there are far fewer MSC in of UCB cell subpopulations that dictates effective, timely engraftment. Current methods of expanding UCB UCB compared to BM (77) . cells do not preserve the quality of the HPC through to EXPANSION NECESSITY the end product (34,54). Recovery of the CD34 + cells from frozen units of UCB is also poor (47) . Current Because of the nature of the source there is but a single opportunity to collect UCB cells and, currently, expansion methods cannot make up for the cells lost in the storage process (31, 43, 68, 71, 83) , let alone augment the number of mononuclear cells (MNC) extracted from that isolated donation is finite. An average procurement them to a suitable dosing regimen. A need for optimizing culture media that maintain the contains only 1.5 × 10 9 cells, which constitutes only 10% of a typical adult dose (adults represent 85% of all primitive nature of the desired subpopulations is needed. Some have demonstrated that coculture with MSC as BM transplant recipients) (6). Furthermore, the standard method by which the MNC are obtained and stored re-support cells may preserve immature, repopulating cells (8, 50, 54) . MSC coculture is advantageous in that no iso-sults in a significant loss of the HPC population; in spite of this, for UCB banking to be fiscally sensible volume lation of the UCB HPC is required, curtailing superfluous loss of cells (54) . However, the MSC used to aid reduction is necessary (53) . Among a number of different methods, extraction of MNC from whole UCB can expansion of UCB HPC are typically of a xenogenic origin, generating the possible introduction of infectious be done through density gradient centrifugation using Ficoll (9). The MNC can then be stored at cryogenic diseases to the patient (81) . Use of an allogenic stromal layer would be difficult due to the extreme rarity of temperatures in minimal space, unlike whole blood. Expansion is central to providing adequate dosing for MSC in UCB (7,28). Expansion challenges keep widespread UCB trans-both children and adults, as well as for recurrent therapy in the event of graft failure. Certain criteria need to be plants in clinical infancy. Simply multiplying the cells globally has proven not to decrease time to engraftment met when considering expansion of UCB cells. First, determining which cells should be expanded. As stated (34,62). Instead, relative proportions of cell subpopulations that home to marrow, form colonies, and reconsti-earlier, UCB contains a large population of CD34 + / CD38 − and CD34 + /CD133 + cells, but also important is tute blood lineages are required. This key clinical obstacle remains elusive to researchers. Continued investigation its component of colony-forming unit (CFU) required for reconstitution of BM and expression of CXCR4 will unveil the true therapeutic potential of UCB for reconstitution of lost or diseased cells. (stromal cell-derived factor-1) involved in homing of cells to the BM where repopulation occurs (19) . Sec-INITIAL ENTHUSIASM OVER UCB ondly, expanded cells also need to maintain telomerase length in order to preserve their pluripotent capacity Clinical applications of UCB to date have focused on hematologic reconstitution. But research suggests multi-(83). Telomerase activity is high in HPC and tends to be most active during proliferation (16) . Table 3 lists a potent cells in the heterogeneous MNC population may differentiate into osteoblasts, chondroblasts, adipocytes, number of laboratories that have had varied success with ex vivo expansion of UCB MNC using different tech-and even neurons and astrocytes (39) . Because of the high proportion of stem/progenitor cells in UCB the niques and medias.
The primary purpose of expansion is to reduce the thought was that it may substitute dependence on use of the highly controversial embryonic and fetal stem cells time to engraftment, thereby increasing treatment success. Therefore, an important consideration for expan-for replacement therapy in a variety of disorders. Several reports have been published claiming the multipotent na-sion of UCB must be the inclusion of neutrophils and platelets. Safety has been established using expanded ture of UCB cells when directed under the right conditions. UCB cells in patients, but the time to neutrophil and platelet engraftment has not successfully been reduced Buzanska et al. (11) used the CD34 − /CD45 − nonhematopoietic MNC fraction of UCB to obtain neural (34,62). The low antigenic response of UCB cells is its driving strong point, leading to lower incidence of stem-like cells. From these, a clonogenic line of human UCB-neural stem cell (NSC), exhibiting immunopheno-GvHD, but it also poses a significant problem. The time to engraftment is delayed compared to BM due to typic markers for nestin and glial fibrillary acidic protein (20) .
Expanded on a monolayer of human BM MSC with cytokines and serum (81) . MSC 1000
In culture with serum for 3 weeks (82).
(GFAP), was derived. In the presence of neuromorpho-vitro-produced, phenotypically similar cells function as their in vivo-derived counterparts. Establishing appro-gen/retinoic acid (RA) 40% of the human UCB-NSC expressed βIII tubulin and MAP-2, 30% expressed the priate function will be crucial before a line of UCB cells can advance toward replacement strategies in the clinic. astrocytic markers GFAP and S100β, and 11% expressed the oligodendrocytic phenotype, galactosylcera-CURRENT RESEARCH mide (GalC). RA + brain-derived neurotrophic factor (BDNF) has also been shown to induce neural differenti-Because of its large population of HPC, UCB was thought to be the ideal source of cells to be used for ation in human UCB-NSC culture. During 7 days of coculture with neuromorphogens, rat astrocytes, or hippo-replacement of dead and/or diseased cells in a number of injuries and diseases. In vivo research has found that campal slices, 80% of cells expressed βIII-tubulin and 64% coexpressed microtubule associated protein (MAP)-human UCB can ameliorate behavioral and physiological consequences in a number of animal disease models, 2, a marker for advanced neuronal differentiation (36). Also, Xiao and colleagues have produced a line of cells the most exciting of which included diseases and injury of the brain. Our lab and others have demonstrated isolated from UCB that they term nonhematopoietic umbilical cord blood stem cells (80). A reduction in infarct UCB's growth as a multidimensional treatment (Table 4) . Linking each disease model with recovery facilitated volume was observed after intravenously transplanting these cells into rats with ischemic brain injury. Histolog-by the use of UCB is the lack of defined mechanism(s). Clearly, UCB works uniquely depending on its environ-ical analysis revealed that some of the transplanted cells were double labeled for human nuclei and NeuN, though ment and the nature of the injury-a presumed molding to fit the need. The multifaceted nature of UCB's thera-it was unlikely that they contributed to the recovery.
Our group has induced expression of neural proteins peutic effects is no doubt a function of its heterogeneous make up, and also is what eludes researchers attempting in UCB MNC. Using a neural proliferation medium consisting of serum-free Dulbecco's modified Eagle's me-to classify its utility. Of course, this is the goal and the necessity before UCB can achieve widespread use in the dium/F12 (DMEM/F12), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and N2 (used for clinic so that the question of safety can be adequately addressed. neural proliferation) and a differentiation medium of DMEM/F12 and N2 supplemented with RA and nerve New research in our lab has found that UCB may growth factor (NGF), Sanchez-Ramos et al. (40, 60) characterization analysis of the cell subpopulations within • Traumatic brain injury (44, 48) cultured UCB, finding neurotrophin receptors in both • Stroke (14, 49, 72, 73, [78] [79] [80] floating and adherent fractions. Exciting though this
• Myocardial infarction (30, 42) may seem, what is not yet known is whether these in 
